A study of the changes of biomarkers for A-703 in healthy adult male smokers
Not Applicable
- Conditions
- Smokers
- Registration Number
- JPRN-UMIN000003604
- Lead Sponsor
- JAPAN TOBACCO INC.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subjects who have regular use experience of hand-rolled cigarette, cigarillo, cigar, pipe, smokeless tobacco or chewing tobacco 2. Subjects who donate 200ml or more of blood within 4 weeks before screening, or who donate 400ml or more of blood within 12 weeks before screening (including blood donation) etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the change of Biomarkers and the nicotine pharmacokinetics during smoking of A-703
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does A-703 target in nicotine addiction or smoking cessation therapies?
How do biomarkers like cotinine or CYP2A6 activity correlate with A-703 efficacy in male smokers?
What comparative effectiveness data exists for A-703 versus nicotine replacement therapies in clinical trials?
What adverse events are associated with A-703 in healthy smokers, and how are they managed pharmacologically?
Are there related compounds or competitor drugs to A-703 in Japan Tobacco Inc.'s pipeline for smoking cessation?